Wire Stories
BeiGene Announces the Approval in China of KYPROLIS� (Carfilzomib) for Injection for Adult Patients with Relapsed or Refractory Multiple Myeloma
BEIJING & CAMBRIDGE, Mass.–(BUSINESS WIRE)–$BGNE #BTKi–BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a global biotechnology company focused on developing and commercializing innovative medicines...